Premium
Evaluation of a 99m Tc‐labelled meso ‐bisphenylporphyrin as a tumour image agent
Author(s) -
Santos Pedro M.,
Laranjo Mafalda,
Serra Arménio C.,
Abrantes Ana Margarida,
Piñeiro Marta,
CasaltaLopes João,
Trindade Diná,
Maia Jorge,
RochaGonsalves António,
Botelho Maria Filomena
Publication year - 2014
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.3180
Subject(s) - chemistry , radiochemistry , nuclear chemistry
Porphyrins are excellent agents for photodynamic treatment of various types of cancer and also good metal chelators that form highly stable metallo‐complexes with different radionuclides. Therefore, radiolabelled porphyrins could also be potentially used as tumour imaging agents. In this context, the aim of this work was the radiolabelling of meso ‐bis[3,4‐bis(carboxymethyleneoxy)phenyl]porphyrin, 2CPP, with Technetium‐99 m ( 99m Tc) and the evaluation of its radiochemical and biological properties in vitro and in vivo . The labelling procedure was optimized resulting in an efficiency of 92.52 ± 0.48%. The complex 99m TC‐2CPP remained stable for more than 4 h. The biodistribution showed that 99m Tc‐2CPP is eliminated by gastrointestinal and urinary pathways. The tumour/muscle ratio increases over time, being 3.33 ± 1.22 and 3.55 ± 1.29 in WiDr‐bearing tumours mice and in H1299‐bearing tumours mice, respectively, 6 h post‐injection, showing the tumour specificity of the 99m Tc‐2CPP complex. The favourable tumour/muscle ratio of 99m Tc‐2CPP shows that this complex could potentially be used as tumour imaging agent. Moreover, it could be used to follow the progression or regression of tumours before, during and after the radiotherapy, chemotherapy and photodynamic therapy. Copyright © 2014 John Wiley & Sons, Ltd.